A Phase II Trial of Epothilone B Analogue BMS-247550 (NSC #710428) (IND 59699) Administered Every 21 Days in Patients with Hormone Refractory Prostate Cancer

Pt must have histologic adenocarcinoma of the prostatewhich is measurable or evaluable Stage D1 or D2. Pts must have metastatic PCa deemed unresponsive or refractory to hormone therapy by criteria in Section 5.2 of the protocol. PSA >/= 5 ng/ml w/in 14 days prior to registration. Mx disease w/in 28 days; non-mx disease w/in 42 days. Pt must have baseline serum sample and agree to have submitted per Section 15.2. CT abd/pelvis w/in 28 days, bone scan w/in 42. Castrated & willing to continue/restart LHRH. At least 28 days out from flutamide or ketoconazole, 42 for bicalutamide or nilutamide. Prior RT >/=28 days prior to reg and to < 30% of bone marrow okay. No prior strontium or samarium. No prior chemo. One prior biologic. PS 0-2. AGC >/= 1500, PLT >/= 100,000, bili </= IULN, SGOT/SGPT </= 2.5 x IULN, creat </= 2.0 or CalcCrCl >/= 40 w/in 7 days. No unconventional therapy (St. John's Wort, PC-SPES). Not planning to begin bisphosphonates. No hx of brain mets.